Apellis Pharmaceuticals (APLS) Projected to Post Earnings on Tuesday

Apellis Pharmaceuticals (NASDAQ:APLS) will likely be posting its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.41) per share and revenue of $199.2760 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Apellis Pharmaceuticals Stock Down 1.6%

Shares of APLS stock opened at $21.70 on Tuesday. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $30.48. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. The firm has a market cap of $2.75 billion, a PE ratio of 70.00 and a beta of 0.26. The stock has a 50 day moving average of $23.50 and a 200-day moving average of $23.92.

Insider Buying and Selling at Apellis Pharmaceuticals

In related news, CFO Timothy Eugene Sullivan sold 10,287 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $21.77, for a total transaction of $223,947.99. Following the completion of the transaction, the chief financial officer directly owned 93,901 shares of the company’s stock, valued at $2,044,224.77. This trade represents a 9.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Cedric Francois sold 27,192 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total transaction of $591,969.84. Following the sale, the chief executive officer directly owned 286,045 shares in the company, valued at $6,227,199.65. This represents a 8.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 120,537 shares of company stock worth $2,608,532 over the last ninety days. Company insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC increased its stake in shares of Apellis Pharmaceuticals by 46.6% in the second quarter. AQR Capital Management LLC now owns 5,976,414 shares of the company’s stock valued at $103,452,000 after buying an additional 1,898,995 shares in the last quarter. Polar Capital Holdings Plc grew its holdings in Apellis Pharmaceuticals by 96.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 2,650,230 shares of the company’s stock worth $59,975,000 after acquiring an additional 1,298,055 shares during the last quarter. Millennium Management LLC increased its position in Apellis Pharmaceuticals by 563.7% in the 3rd quarter. Millennium Management LLC now owns 1,343,726 shares of the company’s stock valued at $30,409,000 after acquiring an additional 1,141,274 shares in the last quarter. Deep Track Capital LP raised its stake in shares of Apellis Pharmaceuticals by 14.3% in the third quarter. Deep Track Capital LP now owns 8,000,382 shares of the company’s stock worth $181,049,000 after acquiring an additional 1,000,382 shares during the last quarter. Finally, Hudson Bay Capital Management LP lifted its position in shares of Apellis Pharmaceuticals by 181.9% during the fourth quarter. Hudson Bay Capital Management LP now owns 1,179,828 shares of the company’s stock worth $29,637,000 after purchasing an additional 761,328 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright reduced their price target on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Stifel Nicolaus cut their price target on Apellis Pharmaceuticals from $55.00 to $48.00 and set a “buy” rating for the company in a report on Friday, December 19th. Cantor Fitzgerald decreased their price objective on Apellis Pharmaceuticals from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Tuesday, January 13th. Barclays began coverage on Apellis Pharmaceuticals in a research report on Wednesday, January 28th. They issued an “equal weight” rating and a $24.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Apellis Pharmaceuticals in a report on Monday, December 29th. Twelve analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $33.00.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.